A Study of LY2940094 in Major Depressive Disorder

Inclusion Criteria:

• Males of any ethnic origin.
• Have a body mass index (BMI) between 19.0 and 30.0 kilogram/square meter (kg/m^2), inclusive.
• Must be in good health, as determined by a medical history, physical examination, 12-lead electrocardiogram (ECG) and clinical laboratory evaluations.
• Have a calculated creatinine clearance of greater than 70 milliliter/minute (mL/min).
• Have venous access sufficient to allow blood sampling as per the protocol.
• Will have given their written informed consent to participate in the study and to abide by the study restrictions.

Exclusion Criteria:

• Male subjects who are not, or whose partners are not willing to use appropriate contraception from the time of the first dose until 3 months after the final dosing occasion.
• Have received any prescribed systemic or topical medication within 14 days of the first dose administration
• Have used any non-prescribed systemic or topical medication (including herbal remedies) within 7 days of the first dose administration (with the exception of vitamin/mineral supplements) unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise safety.
• Have received any medications, including St John's Wort, known to chronically alter drug absorption or elimination processes within 30 days of the first dose administration
• Currently enrolled in, have completed or discontinued within the last 30 days from, a clinical trial involving an investigational product or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
• Have donated or lost 50 to 499 milliliter (mL) of whole blood within 30 days, or more than 499 milliliter (mL) whole blood within 56 days preceding first dose administration.
• Have a significant history of drug allergy as determined by the Investigator.
• Have any clinically significant allergic disease (excluding non-active hay fever), or any known allergy to LY2940094 or excipients as determined by the Investigator.
• Have a semi-reclined blood pressure and pulse rate higher than 130/90 millimeters of mercury (mmHg) and 100 beats per minute (bpm), respectively, or lower than 90/50 millimeters of mercury (mmHg) and 40 beats per minute (bpm), respectively.
• Consume more than 28 units of alcohol per week or who have a significant history of alcoholism or drug/chemical abuse/dependence as determined by the Investigator.
• Have a positive urine drug screen or alcohol breath test result that indicates substance abuse at screening or at admission to any treatment period.
• Smoke more than 10 cigarettes or the equivalent in tobacco per day and willing to avoid smoking for durations of at least 10 hours.
• With, or with a history of, any clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, hematological or other major disorders as determined by the Investigator.
• Have had a clinically significant illness within 4 weeks of the start of dose administration as determined by the Investigator.
• Have serum hepatitis, or who are carriers of the hepatitis B surface antigen (HBsAg) or hepatitis C antibody, or who have a positive result to the test for human immunodeficiency virus (HIV) antibodies.

• Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risk of participating in the study. In addition, subjects with the following findings will be excluded:

  • Confirmed Bazett's corrected QT (QTcB) interval greater than 450 millisecond (msec) in 2 of 3 electrocardiograms (ECGs).
  • Bundle branch blocks and other conduction abnormalities (including 2nd or 3rd degree Atrioventricular block, complete left bundle branch block, complete right bundle branch block or Wolffe-Parkinson-White Syndrome, defined as PR less than 110 milliseconds (msec),confirmed by a repeat electrocardiogram [ECG]) other than mild first-degree atrioventricular block (AV) block.
  • Irregular rhythms other than sinus arrhythmia or occasional rare supraventricular ectopic beats.
  • History of unexplained syncope.
  • Family history of unexplained syncope or sudden death due to long QT syndrome.
  • T wave configurations are not of adequate quality for assessing QTc intervals.
• Have previously completed or been withdrawn from this study.
• Taking any excluded medications that cannot be discontinued at Screening.
• Have a personal or family history of recurrent seizures or complicated febrile seizures.
• Have a history of significant brain trauma.
• Have epileptiform activity on baseline electroencephalogram (EEG).